

Accepted Manuscript

Review

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?

Neil Rajoriya, Christophe Combet, Fabien Zoulim, Harry L.A. Janssen


PII: S0168-8278(17)32154-2
DOI: <http://dx.doi.org/10.1016/j.jhep.2017.07.011>
Reference: JHEPAT 6602

To appear in: *Journal of Hepatology*

Received Date: 3 January 2017
Revised Date: 27 June 2017
Accepted Date: 12 July 2017

Please cite this article as: Rajoriya, N., Combet, C., Zoulim, F., Janssen, H.L.A., How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?, *Journal of Hepatology* (2017), doi: <http://dx.doi.org/10.1016/j.jhep.2017.07.011>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?

Authors:

Neil Rajoriya¹, Christophe Combet², Fabien Zoulim^{2,3}, Harry L.A. Janssen¹

¹Toronto Centre for Liver Diseases, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada, M5G2C4

²Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, 69XXX, France

³Department of Hepatology, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.

Corresponding author:

Professor HLA Janssen

Toronto Centre for Liver Diseases, Toronto General Hospital, Toronto, Ontario, Canada

Email: Harry.Janssen@uhn.ca

Keywords:

Hepatitis B, genotype, personalized medicine

Word count: (excluding abstract and references):7032

No of figures: 4

No of tables:4

Conflicts of interest/disclosures:

NR – none to declare

CC received a grant and training fees from Gilead.

FZ received grants through INSERM and/or consulting fees from Arbutus, Assembly, Contravir, Gilead, Janssen, Novira, Roche, Sanofi and Transgene.

HLAJ received grants from Abbvie, Bristol Myers Squibb, Gilead Sciences, Innogenetics Janssen, Medimmune, Merck, Novartis and Roche. HLAJ is a consultant for AbbVie, Benetic, Bristol Myers Squibb, Gilead Sciences, Janssen, Medimmune, Merck, Novartix, Roche and Arbutus.

Contributions:

NR wrote the 1st draft of paper, led with revisions and submission of manuscript.

CC contributed to manuscript drafting and revisions.

FZ co-contributed to paper revisions.

HLAJ contributed to revisions of manuscript and supervision of co-authors.

Download English Version:

<https://daneshyari.com/en/article/8729741>

Download Persian Version:

<https://daneshyari.com/article/8729741>

[Daneshyari.com](https://daneshyari.com)